Concepedia

Bart Claes

BC

Statistics

Publications

32

Citations

6.5K

H-Index

25

Active since

1989

Affiliations

KU Leuven(Current)

Ghent University

Biocartis (Belgium)

Université Paris Cité

Institut Jules Bordet

Bart Claes is an author at KU Leuven specializing in medicine, oncology, and pathology.

Top concepts

Publications per year

1989–2021

32

Publications

32

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

, , +5

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Tim Maughan, Richard Adams, Christopher G. Smith et al. · The Lancet · 2011 · 964 citations

, , +8

Thrombomodulin Mutations in Atypical Hemolytic–Uremic Syndrome

Mieke Delvaeye, Marina Noris, Astrid De Vriese et al. · New England Journal of Medicine · 2009 · 542 citations · Full text

Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene

Wim Janssens, Roger Bouillon, Bart Claes et al. · Thorax · 2009 · 457 citations · Full text

PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

Hans Prenen, Jef De Schutter, Bart Jacobs et al. · Clinical Cancer Research · 2009 · 293 citations · Full text

Rows per page

1–5 of 32